The U.S. Centers for Disease Control and Prevention (CDC) on Sept. 24 backed a booster shot of the Pfizer and BioNTech Covid-19 vaccine for Americans aged 65 and older, adults with underlying medical conditions and adults in high-risk working and institutional settings.

Booster shots to bolster immunity against the coronavirus would be free and accessible, U.S. President Joe Biden said on Friday, one day after federal health agencies backed a booster rollout.

Advisers to the U.S. Food and Drug Administration voted on Sept. 17 to recommend Covid-19 vaccine booster shots for Americans 65 and older and those at high risk of severe illness, after overwhelmingly rejecting a call for broader approval.

Heading into fall, with the Covid-19 pandemic surging again and researchers tracking new variants, there is plenty of news. BioSpace takes a look, including several research studies suggesting that some people have unusually strong immunity against Covid-19.

President Joe Biden on Sept. 9 will present a six-pronged strategy intended to fight the spread of the highly contagious coronavirus Delta variant and increase U.S. Covid-19 vaccinations, the White House said on Sept. 7.

75 percent of adults in the United States have received at least one dose of a Covid-19 vaccine as of the morning of Sept. 7, the U.S. Centers for Disease Control and Prevention said.

A study published in the Journal of the American Medical Association by Belgium researchers comparing the Moderna and Pfizer-BioNTech Covid-19 vaccines found that the Moderna jabs generated twice the antibodies as the Pfizer-BioNTech vaccine.

Around 14 million people in the United States received their first dose of a Covid-19 vaccine in August, about 4 million more than in July, officials said on Aug. 31 as the government pushes inoculation as infections rise.

An advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) on Aug. 30 unanimously recommended the Pfizer Inc. and BioNTech SE Covid-19 vaccine for people age 16 and older, an important step that could help accelerate vaccine mandates in the United States.

Participants in Novavax Inc.’s late-stage Covid-19 vaccine trial can be considered fully vaccinated two weeks after completing their two-dose vaccine regimen, the U.S. Centers for Disease Control and Prevention said on Aug. 30.